Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEW-HOPE: Firibastat in hypertensive overweight subjects
NCT03198793Phase 2Completed
- Sponsor
- Quantum Genomics
- Start
- Oct 2017
- Primary completion
- Oct 2018
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of firibastat in hypertension (HTN), sponsored by Quantum Genomics. Primary endpoint: Change in office systolic blood pressure from baseline at 8 weeks. Started Oct 2017; status: completed.
02
Drugs
firibastat
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT03198793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03198793.